Unknown PHASE3 INTERVENTIONAL 2-arm NCT06071949

Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis

Sponsor: Apurano Pharmaceuticals GmbH

Conditions Central Neuropathic Pain Chronic Pain Chronic Pain Syndrome Multiple Sclerosis Neuropathic Pain Pain Pain Syndrome Pain, Chronic Paraplegia Phantom Limb Syndrome With Pain Phantom Pain Stroke Traumatic Brain Injury

Interventions Adezunap Placebo

Updated 5 times since 2023 Last updated: Jan 30, 2024 Started: Nov 2, 2023 Primary completion: Sep 30, 2024 Completion: Dec 31, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Central Neuropathic Pain and Chronic Pain and is currently ongoing. Apurano Pharmaceuticals GmbH leads this study, which shows 5 recorded versions since 2023 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Oct 2025 — Present [monthly]

Unknown PHASE3

Status: Recruiting → Unknown
Sep 2024 — Oct 2025 [monthly]

Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE3
Feb 2024 — Jul 2024 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Nov 2023 — Feb 2024 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Apurano Pharmaceuticals GmbH

Data source: Apurano Pharmaceuticals GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Munich, Germany